Simulect 20 mg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Simulect 20 mg Injection contains basiliximab, an interleukin-2 receptor antagonist (monoclonal antibody). Its labelling describes it for the prophylaxis of acute organ rejection in patients receiving a kidney transplant, used together with other immunosuppressive medicines. It is administered only by a healthcare professional and is not self-administered.
Product Information
The following description reflects information associated with basiliximab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the prevention of acute rejection of a transplanted kidney
- Described as used together with other immunosuppressive medicines
- Described as suppressing the immune response that would otherwise attack the transplanted organ
Described Dosage & Administration
- Administered only by a doctor or nurse as an injection or infusion — not self-administered
- The dose, number of doses, and timing set by the transplant team should be followed
- The stated dose should not be exceeded, as overdosing is described as increasing the risk of serious side effects
Described Side Effects
Commonly described side effects include:
- Nausea, vomiting, and indigestion
- Constipation, diarrhoea, and abdominal pain
- Headache and generalised pain
- Weight gain and swelling of the hands
- High blood pressure
- Anaemia (low number of red blood cells)
- Injection-site reactions (pain, swelling, redness)
These are described as often settling with time. Any severe, persistent, or unexpected reaction — including signs of a serious allergic reaction — requires prompt medical attention.
Precautions
- The doctor should be informed if the recipient is pregnant or breastfeeding
- Full medical records and a list of all current medicines should be shared with the transplant team
- Any previous allergic reaction to basiliximab or a similar product should be disclosed beforehand
- Any severe or persistent side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains basiliximab and is used to help prevent acute rejection of a transplanted kidney, together with other immunosuppressive medicines. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an injection or infusion in a hospital setting, at the dose and schedule set by the transplant team. It is not self-administered.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.